Paris Pharmaceuticals is based in France and is planning to enter the U.S.market to sell its new hypertension medicine there.Which of the following is not an appropriate entry mode for the company?

Question

Quizplus · Accepted Answer

Exporting utilizing U.S.-based contract manufacturers may not be an appropriate entry mode as it involves partnering with a third-party manufacturer, which may not offer complete control over the production process and the quality of the product. Additionally, it may not be cost-effective for Paris Pharmaceuticals to establish a production facility in the U.S. as it may require significant capital investment and may involve regulatory hurdles. The most appropriate entry mode for the company would be to license the product to a U.S. pharmaceutical firm or to form a distribution-based alliance with a U.S. pharmaceutical firm as this would provide access to established distribution networks and existing customer bases. Exporting utilizing distributors may also be a viable option as it would involve minimum investment and allow the company to test the waters before committing to a more significant investment.

Paris Pharmaceuticals Is Based in France and Is Planning to Enter